AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative visualization of blue lymphatic vessels
Number of subjects: 174
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 174
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of SLN identified
Number of subjects: 174
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: pN2 stage
Number of subjects: 174
Study 23354923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body mass index (BMI)
Number of subjects: 174
Study 23355122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (mean step count = 8,575 ± 3,191)
Number of subjects: 223
Study 23355122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 223
Study 23355122 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 3 or more MetS traits
Number of subjects: 223
Study 23355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-decision prompts on hospital elevator doors promoting stair use
Number of subjects: 11000
Study 23355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-purchase prompts in the hospital restaurant promoting reduced-salt soup
Number of subjects: 11000
Study 23355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-purchase prompts in the hospital restaurant promoting lean croissants
Number of subjects: 11000
Study 23355669 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal of the accessibility and availability of diet margarine and butter in the hospital restaurant
Number of subjects: 11000
Study 23355673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg daily for 42 days
Number of subjects: 150
Study 23355673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 42 days
Number of subjects: 150
Study 23355673 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 0.3 ml subcutaneously for 42 days
Number of subjects: 150
Study 23356818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-European races (black Africans, Chinese, Japanese)
Number of subjects: 2580
Study 23356818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese
Number of subjects: 2580
Study 23356818 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese
Number of subjects: 2580
Study 23356818 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Africans
Number of subjects: 2580
Study 23356818 — intervention group
Group type: COMPARATOR
Intervention: Europeans
Number of subjects: 2580
Study 23357569 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 2511
Study 23358617 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (DAR) 500 μg once every 2 weeks for 12 weeks
Number of subjects: 99
Study 23358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated malaria
Number of subjects: 1933
Study 23358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malaria
Number of subjects: 1933
Study 23358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria, hypoxia, severe thrombocytopenia, leukocytosis, lactic acidosis
Number of subjects: 1933
Study 23358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia, splenomegaly, leukocytosis
Number of subjects: 1933
Study 23358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Death, severe thrombocytopenia, lactic acidosis, cerebral malaria, hypoxia, hypoglycemia, hyper-parasitemia
Number of subjects: 1933
Study 23358817 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography coronary angiography (CTCA)
Number of subjects: 1000
Study 23359181 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) followed by Irinotecan (350 mg/m²) every 21 days
Number of subjects: 53
Study 23359360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 57
Study 23359362 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study 23359362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 23359515 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIT1 duplication
Number of subjects: 40
Study 23360920 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation for nonresectable CLMs
Number of subjects: 21
Study 23361157 — intervention group
Group type: EXPERIMENTAL
Intervention: Irish participants
Number of subjects: 324
Study 23361157 — intervention group
Group type: COMPARATOR
Intervention: Spanish participants
Number of subjects: 324
Study 23361157 — intervention group
Group type: COMPARATOR
Intervention: Icelandic participants
Number of subjects: 324
Study 23361508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3-2.0 mg/eye) administered intravitreally (ITV) biweekly or monthly for up to 24 months
Number of subjects: 674
Study 23361508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 and 0.5 mg/eye) administered ITV monthly and quarterly
Number of subjects: 674
Study 23361508 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic analysis
Number of subjects: 674
Study 23362021 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM) sessions
Number of subjects: 1650
Study 23362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking desaturation score (0-6)
Number of subjects: 673
Study 23362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking desaturation score categories (low 0-1, high 2-3, very high 4-6)
Number of subjects: 673
Study 23362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 673
Study 23362168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hosmer-Lemeshow goodness-of-fit test
Number of subjects: 673
Study 23362308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of progenitor cells
Number of subjects: 775
Study 23363496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2767
Study 23363496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 2767
Study 23363496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2767
Study 23364010 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 1346
Study 23364010 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 1346
Study 23364010 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) measures
Number of subjects: 1346
Study 23364010 — intervention group
Group type: COMPARATOR
Intervention: Anthropometric measures
Number of subjects: 1346
Study 23364011 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D deficiency (<10 ng/mL)
Number of subjects: 1080
Study 23364011 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D insufficiency (10.0-19.9 ng/mL)
Number of subjects: 1080
Study 23364011 — intervention group
Group type: COMPARATOR
Intervention: 25(OH)D sufficiency (≥20 ng/mL)
Number of subjects: 1080
Study 23364011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of T2D
Number of subjects: 1080
Study 23364320 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 23364320 — intervention group
Group type: COMPARATOR
Intervention: Traditional NSAID therapy
Number of subjects: 0
Study 23369084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.20 mm diameter angioplasty catheter
Number of subjects: 71
Study 23369112 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand valve oxygen
Number of subjects: 4
Study 23369112 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow oxygen
Number of subjects: 4
Study 23369230 — intervention group
Group type: EXPERIMENTAL
Intervention: Random capillary glucose (RCG)
Number of subjects: 398
Study 23369230 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA diabetes risk test (DRT)
Number of subjects: 398
Study 23369230 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin fluorescence spectroscopy (SFS)
Number of subjects: 398
Study 23369437 — intervention group
Group type: EXPERIMENTAL
Intervention: Shotgun proteomics analysis of urine samples from patients with acute rejection (AR)
Number of subjects: 12
Study 23369437 — intervention group
Group type: COMPARATOR
Intervention: Shotgun proteomics analysis of urine samples from age-matched controls
Number of subjects: 12
Study 23369458 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction combined with early steroid reduction to 5 mg/day, low dose cyclosporine (C2 target of 600 to 800 ng/ml), and mycophenolic acid (MPA) therapy
Number of subjects: 49
Study 23369458 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort treated with Thymoglobulin induction, conventional doses of cyclosporine and corticosteroids
Number of subjects: 49
Study 23370048 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based nutrition education interventions
Number of subjects: 8722
Study 23370203 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Graeb Score (mGS)
Number of subjects: 435
Study 23370203 — intervention group
Group type: COMPARATOR
Intervention: Original Graeb Scale
Number of subjects: 435
Study 23370503 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anxiety (measured by HADS-Anxiety score)
Number of subjects: 148
Study 23370503 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of depressive symptoms (measured by HADS-Depression score)
Number of subjects: 148
Study 23370503 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of anxiety and depression
Number of subjects: 148
Study 23370599 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg nebulized iloprost
Number of subjects: 20
Study 23371395 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 2398
Study 23372266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg ZST
Number of subjects: 295
Study 23372266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 23372270 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP with C-Flex
Number of subjects: 93
Study 23372270 — intervention group
Group type: COMPARATOR
Intervention: APAP
Number of subjects: 93
Study 23372270 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP with A-Flex
Number of subjects: 93
Study 23372269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration and latency
Number of subjects: 191
Study 23372269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 191
Study 23372269 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 191
Study 23372690 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS
Number of subjects: 84
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive laminectomy without fusion
Number of subjects: 40
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet angle > 50°
Number of subjects: 40
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc height > 6.5 mm
Number of subjects: 40
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion at spondylolisthesis > 1.25 mm
Number of subjects: 40
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 risk factors (motion at spondylolisthesis > 1.25 mm, disc height > 6.5 mm, facet angle > 50°)
Number of subjects: 40
Study 23373567 — intervention group
Group type: EXPERIMENTAL
Intervention: No risk factors for instability
Number of subjects: 40
Study 23374856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pam3CSK4 (specific TLR2/1 ligand)
Number of subjects: 34
Study 23374856 — intervention group
Group type: COMPARATOR
Intervention: TLR expression on lung CD8+ T cells
Number of subjects: 34
Study 23374856 — intervention group
Group type: COMPARATOR
Intervention: TLR expression on lung CD4+ T cells and CD8+ NKT cells
Number of subjects: 34
Study 23374856 — intervention group
Group type: COMPARATOR
Intervention: TLR expression on lung CD56+ NK cells
Number of subjects: 34
Study 23374970 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation procedure with high left atrial appendage peak flow velocity (LAV >0.3 m/s)
Number of subjects: 40
Study 23374979 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT) with 54 Gy and 5-fluorouracil-based regimen
Number of subjects: 99
Study 23374979 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive inguinal node uptake after CRT (positive PET at baseline and 12 weeks)
Number of subjects: 99
Study 23374979 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive inguinal node uptake
Number of subjects: 99
Study 23375202 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants rs3797179 (SRD5A1), rs12473543 (POMC), and rs1501299 (ADIPOQ)
Number of subjects: 997
Study 23375202 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in the FBN3 gene (rs17202517 and rs73503752)
Number of subjects: 997
Study 23375202 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs727428 in the SHBG gene
Number of subjects: 997
Study 23375202 — intervention group
Group type: COMPARATOR
Intervention: Previously identified variants in candidate genes
Number of subjects: 997
Study 23375329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of autologous bone marrow concentrate
Number of subjects: 13
Study 23375478 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT measurement at 3 hours
Number of subjects: 306
Study 23375478 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT diagnostic algorithm
Number of subjects: 306
Study 23375478 — intervention group
Group type: COMPARATOR
Intervention: Cumulative survival
Number of subjects: 306
Study 23375717 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of ≥5% of initial weight
Number of subjects: 220
Study 23375717 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of ≥5% of initial weight at 6 months
Number of subjects: 220
Study 23375717 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at 18 months
Number of subjects: 220
Study 23375908 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (BM)
Number of subjects: 0
Study 23375908 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula (SF)
Number of subjects: 0
Study 23375908 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula (CMF) and Soy formula (SF)
Number of subjects: 0
Study 23375926 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training (twice-weekly 60-min sessions for 3 months)
Number of subjects: 0
Study 23375926 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training
Number of subjects: 0
Study 23376426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sample OC Sensor FIT
Number of subjects: 19797
Study 23376426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sample Magstream FIT
Number of subjects: 19797
Study 23376426 — intervention group
Group type: COMPARATOR
Intervention: Hemoccult II guaiac test
Number of subjects: 19797
Study 23377438 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (1.44 μg/kg/h) during pVOC
Number of subjects: 27
Study 23377586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 37
Study 23377664 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA peptide-pulsed DCs
Number of subjects: 34
Study 23377664 — intervention group
Group type: COMPARATOR
Intervention: ATL-pulsed DC vaccination
Number of subjects: 34
Study 23377664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GAA-DC and ATL-DC
Number of subjects: 34
Study 23377668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3 TCR-engineered T cells
Number of subjects: 9
Study 23377993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in susceptible individuals
Number of subjects: 200
Study 23377993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in non-susceptible individuals
Number of subjects: 200
Study 23377993 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 200
Study 23377993 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy smokers
Number of subjects: 200
Study 23377993 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-biased approaches such as proteomics
Number of subjects: 200
Study 23378284 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 30-μg doses of unadjuvanted, inactivated pH1N1 vaccine 21 days apart
Number of subjects: 127
Study 23379680 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC60 regimen
Number of subjects: 60
Study 23379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Human coronaviruses (HCoVs) detection in patients with AGE
Number of subjects: 260
Study 23379823 — intervention group
Group type: COMPARATOR
Intervention: Human coronaviruses (HCoVs) detection in controls
Number of subjects: 260
Study 23379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HCoVs in nasopharyngeal (NP) samples from patients with AGE
Number of subjects: 260
Study 23379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HCoVs in stool samples from patients with AGE
Number of subjects: 260
Study 23379823 — intervention group
Group type: COMPARATOR
Intervention: Detection of HCoVs in stool samples from controls
Number of subjects: 260
Study 23379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of HCoV detection in stool samples
Number of subjects: 260
Study 23379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of HCoV detection in stool and/or NP samples
Number of subjects: 260
Study 23380277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bafetinib 240 or 360 mg po, administered twice with a 12-hour interval
Number of subjects: 7
Study 23380471 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of 2782 ± 19 hours of daylight
Number of subjects: 235
Study 23380471 — intervention group
Group type: COMPARATOR
Intervention: Average of 1681 ± 24 hours of daylight
Number of subjects: 235
Study 23380715 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for predicting treatment resistance
Number of subjects: 0
Study 23380715 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve Bayes classifier, support vector machine, random forest model
Number of subjects: 0
Study 23380715 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sociodemographic and clinical features
Number of subjects: 0
Study 23382117 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-labeled mature DCs with additional intradermal vaccination
Number of subjects: 0
Study 23382117 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment with nonloaded, activated DCs, TNFα, or Imiquimod
Number of subjects: 0
Study 23382117 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphy
Number of subjects: 0
Study 23382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured systolic blood pressure (SBP)
Number of subjects: 1130
Study 23382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual systolic blood pressure (SBP)
Number of subjects: 1130
Study 23382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured diastolic blood pressure (DBP)
Number of subjects: 1130
Study 23382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual diastolic blood pressure (DBP)
Number of subjects: 1130
Study 23382400 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual pulse pressure (PP)
Number of subjects: 1130
Study 23382403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium intervention (51.3 mmol sodium/day)
Number of subjects: 1906
Study 23382403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium intervention (307.8 mmol sodium/day)
Number of subjects: 1906
Study 23382471 — intervention group
Group type: EXPERIMENTAL
Intervention: LN involvement
Number of subjects: 569
Study 23382471 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic residual disease
Number of subjects: 569
Study 23382471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stage III favorable-histology Wilms tumor
Number of subjects: 569
Study 23382909 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat
Number of subjects: 0
Study 23383236 — intervention group
Group type: EXPERIMENTAL
Intervention: CLI patients
Number of subjects: 101
Study 23383236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC from CLI patients
Number of subjects: 101
Study 23383236 — intervention group
Group type: EXPERIMENTAL
Intervention: BM CD34(+) cell levels in CLI patients
Number of subjects: 101
Study 23383749 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 243
Study 23384490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported maximum walking distance (MWD)
Number of subjects: 31
Study 23384490 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 31
Study 23384490 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of Ambulatory Capacity by History-Questionnaire (EACH-Q)
Number of subjects: 31
Study 23384490 — intervention group
Group type: COMPARATOR
Intervention: Incremental treadmill walking test
Number of subjects: 31
Study 23384490 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test
Number of subjects: 31
Study 23384495 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Valiant Captivia stent graft
Number of subjects: 50
Study 23384627 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (PC20 measurement)
Number of subjects: 88
Study 23385153 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling with cervico-vaginal brush and iFTA elute cards
Number of subjects: 632
Study 23385153 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women treated with cryotherapy after VIA triage
Number of subjects: 632
Study 23385153 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months after treatment
Number of subjects: 632
Study 23385153 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant satisfaction with the screening program
Number of subjects: 632
Study 23385197 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.5 mg/m², intravenously over 24 hours, repeated every 21 days)
Number of subjects: 1895